Overview

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Status:
RECRUITING
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
Cisplatin
Docetaxel
Injections
pamiparib
tislelizumab